Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3437 - Pharmacokinetic (PK) study of a single oral dose of NEPA in Chinese healthy volunteers (HVs)

Date

10 Sep 2017

Session

Poster display session

Presenters

Rui Chen

Citation

Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388

Authors

R. Chen1, S. Chessari2, C. Lanzarotti2, A. Bernareggi3, P. Hu1

Author affiliations

  • 1 Clinical Pharmacology Research Center, Peking Union Medical College Hospital (PUMCH), 100032 - Beijing/CN
  • 2 Corporate Clinical Development, Helsinn Healthcare SA, Lugano/CH
  • 3 R & D Innovation And Strategy, Helsinn Healthcare SA, Lugano/CH
More

Resources

Abstract 3437

Background

NEPA, a combined neurokinin-1 receptor antagonist (RA) netupitant (NETU; 300 mg) and 5-HT3–RA palonosetron (PALO; 0.50 mg), is the first approved oral combination antiemetic. NEPA has shown superior efficacy over PALO in preventing chemotherapy-induced nausea and vomiting (CINV), in cisplatin and AC-chemotherapy settings, leading to its approval in the US and Europe (with 85% of patients Caucasian in the clinical trials). A recent phase 3 registration trial in Asian patients demonstrated non-inferiority of a single oral dose of NEPA in preventing CINV compared with a 3-day oral aprepitant/granisetron regimen. The present study was undertaken to assess the PK profile of NETU and PALO in Chinese HVs.

Methods

Eligible HVs received a single oral dose of NEPA administered as a hard gelatin capsule on day 1, after 10-h fasting. Blood samples for PK analysis were collected pre-dose and at 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, and 240 h post-dose. The plasma concentration of NETU and PALO was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). PK parameters were estimated via non-compartmental analysis using the WinNonlin 6.3 software (Certara Inc., Princeton, NJ, USA).

Results

A total of 18 subjects were enrolled (16 male; median body weight 62.7 kg [52.6–75.2 kg]; median age 27 y [21–37 y]). After a single oral dose of NEPA, mean (±SD) values of peak plasma concentration (Cmax) for NETU were 698±217 ng/mL at a median of 4.5 h (Tmax; 3–6 h), with mean (±SD) overall exposure up to the last measurable concentration (AUC0–t) of 20.2±3.93 h*mg/L. PALO plasma concentrations reached mean (±SD) Cmax of 1800±252 ng/mL at 3 h (2–6 h) with mean (±SD) AUC0–t of 77.6±13.3 h*µg/L. NEPA was well tolerated in all HVs.

Conclusions

In Chinese HVs the PK profile of NETU was comparable to that previously observed in Caucasians. For PALO, Cmax and AUC0–t were higher in these Chinese HVs compared to Caucasians, which may be explained by CYP2D6 (involved in the metabolism of PALO) polymorphism. However, the similar efficacy and safety for PALO and NEPA in pivotal studies in both populations suggests that the higher exposure to PALO in Chinese HVs is unlikely to be clinically relevant.

Clinical trial identification

Legal entity responsible for the study

Helsinn Healthcare SA

Funding

Helsinn Healthcare SA

Disclosure

S. Chessari, C. Lanzarotti, A. Bernareggi: Helsinn Healthcare SA employee

\r\n

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.